CRISPR THERAPTC (CRSP) and Cellular Dynamics International (ICEL) Critical Analysis
CRISPR THERAPTC (NASDAQ: CRSP) and Cellular Dynamics International (NASDAQ:ICEL) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitabiliy, institutional ownership, risk, earnings, dividends and analyst recommendations.
This is a breakdown of recent recommendations and price targets for CRISPR THERAPTC and Cellular Dynamics International, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cellular Dynamics International||0||0||0||0||N/A|
CRISPR THERAPTC currently has a consensus price target of $21.92, suggesting a potential upside of 18.47%. Given CRISPR THERAPTC’s higher probable upside, equities analysts clearly believe CRISPR THERAPTC is more favorable than Cellular Dynamics International.
This table compares CRISPR THERAPTC and Cellular Dynamics International’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cellular Dynamics International||-88.12%||-57.59%||-38.09%|
Insider & Institutional Ownership
24.1% of CRISPR THERAPTC shares are owned by institutional investors. 40.0% of CRISPR THERAPTC shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares CRISPR THERAPTC and Cellular Dynamics International’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|CRISPR THERAPTC||$7.39 million||100.13||-$75.68 million||N/A||N/A|
|Cellular Dynamics International||N/A||N/A||N/A||N/A||N/A|
Cellular Dynamics International has higher revenue, but lower earnings than CRISPR THERAPTC.
CRISPR THERAPTC beats Cellular Dynamics International on 8 of the 8 factors compared between the two stocks.
About CRISPR THERAPTC
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA), which is comprised of a crRNA component and a tracrRNA component, either individually or combined together as a single guide RNA. The Company has business operations in London, the United Kingdom, as well as research and development operations in Cambridge, the United States.
About Cellular Dynamics International
Cellular Dynamics International, Inc. develops and produces functioning human cells in industrial quantities. The Company’s products include true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell products). It markets its products for use in life science in vitro research and development, as well as applied product testing, stem cell banking and in vivo cellular therapeutics. It is also in the process of developing human cells as cellular therapeutics. The market for in vitro drug discovery, toxicity testing and applied testing, including chemical safety, has employed models, such as primary cells, transformed (immortalized) cells and live animals that act as surrogates for functioning human cells. Its iCell and MyCell products consist of iCell Cardiomyocytes, iCell Neurons, iCell DopaNeurons, iCell Endothelial Cells, iCell Hepatocytes, MyCell and Media and reprogramming kit.
Receive News & Ratings for CRISPR THERAPTC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR THERAPTC and related companies with MarketBeat.com's FREE daily email newsletter.